Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study
Abstract Background There is ongoing controversy regarding abacavir use in the treatment of HIV infection and the risk of subsequent development of cardiovascular disease. It is unclear how the risk varies as exposure accumulates. Methods Using an administrative health-plan dataset, risk of cardiova...
Main Authors: | Kunchok Dorjee, Sanjiv M. Baxi, Arthur L. Reingold, Alan Hubbard |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-10-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12879-017-2808-8 |
Similar Items
-
Estimated use of abacavir among adults and children enrolled in public sector antiretroviral therapy programmes in Gauteng, South Africa
by: D Evans, et al.
Published: (2012-08-01) -
Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States
by: Kunchok Dorjee, et al.
Published: (2021-09-01) -
Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
by: Langdahl Bente L, et al.
Published: (2011-10-01) -
Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
by: Saye H. Khoo, et al.
Published: (2011-06-01) -
Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
by: Wolf E, et al.
Published: (2010-04-01)